GetTopicDetailResponse(id=d181648e070, topicName=法米替尼, introduction=法米替尼, content=null, image=null, comments=0, allHits=1287, url=https://h5.medsci.cn/topic?id=64870, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=19561, tagList=[TagDto(tagId=19561, tagName=法米替尼)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2249670, encodeId=529f22496e0e7, content=<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#結(jié)直腸癌#</a> <a href='/topic/show?id=d181648e070' target=_blank style='color:#2F92EE;'>#法米替尼#</a> <a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠單抗#</a>, objectTitle=The Innovation | 法米替尼聯(lián)合卡瑞利珠單抗：晚期結(jié)直腸癌患者的有效治療選擇, objectType=article, longId=861045, objectId=9346861045f0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250125/1737815809805_6145188.png, objectUrl=/article/show_article.do?id=9346861045f0, replyNumber=0, likeNumber=43, createdTime=2025-01-26, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=9346861045f0, moduleTitle=The Innovation | 法米替尼聯(lián)合卡瑞利珠單抗：晚期結(jié)直腸癌患者的有效治療選擇, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9346861045f0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2190991, encodeId=ba9a2190991db, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=d181648e070' target=_blank style='color:#2F92EE;'>#法米替尼#</a> <a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠單抗#</a>, objectTitle=超50%患者客觀緩解！樊嘉、周彩存合作團(tuán)隊(duì)：新療法助力晚期肺癌患者病情顯著改善, objectType=article, longId=815790, objectId=1372815e90db, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, objectUrl=/article/show_article.do?id=1372815e90db, replyNumber=0, likeNumber=144, createdTime=2024-03-04, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1372815e90db, moduleTitle=超50%患者客觀緩解！樊嘉、周彩存合作團(tuán)隊(duì)：新療法助力晚期肺癌患者病情顯著改善, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1372815e90db)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯話題小助手
2020-05-29
